We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Chemoembolization for Liver Cancer

By HospiMedica staff writers
Posted on 14 Apr 2005
Two-thirds of liver cancer patients have inoperable tumors and could benefit from a nonsurgical treatment option that delivers a high dose of chemotherapy to a tumor while decreasing blood flow through the arteries feeding the tumor, according to the results of several new studies.

Called chemoembolization, this option allows chemotherapeutic drugs to remain localized to the tumor, decreasing harm to healthy tissues and allowing higher doses of the drugs to be used. More...
Chemoembolization does not induce liver toxicity, the studies showed, but offers patients additional months, and is even safe for high-risk liver cancer patients who already have restricted blood flow in the liver due to portal vein thrombosis.

Although surgical removal of liver tumors offers the best chance for a cure, many are inoperable because they are too large or have grown into major blood vessels or other vital structures. Sometimes, many small tumors are spread throughout the liver, making surgery too risky or impractical. More than two-thirds of liver cancer patients and 90% of those with metastatic cancer cannot have surgery. Doctors need to ensure that cancer treatments do not cause additional liver damage and toxicity.

In chemoembolization, a doctor threads a tiny catheter up the femoral artery in the groin into the blood vessels supplying the liver tumor. The embolic agents keep the chemotherapy drug localized to the tumor while depriving the tumor of blood needed for its growth. The procedure usually involves a hospital stay of two to four days.

"The safety study shows that chemoembolization should be the standard first-line treatment for inoperable liver tumors,” noted Jeff. Geschwind, M.D., director of interventional radiology and associate professor at Johns Hopkins University School of Medicine (Baltimore, MD, USA).




Related Links:
Johns Hopkins School of Medicine

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
New
Digital Radiography System (Ceiling Free)
Digix CF Series
New
Blood Pressure Monitor
Cuff Blood Pressure Monitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.